Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002168 · ClinicalTrials.gov registry record · NA
Determining Lipid Content in Stool After Alpha-cyclodextrin
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03002168: Completed NA study, sponsored by Mayo Clinic.
NCT03002168 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03002168, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The Investigator hypothesizes that the currently used dose of dietary ingredient alpha-cyclodextrin (α-CD) will result in greater loss of dietary fat in the stool compared with placebo. The proposed studies will address the degree to which α-CD increases dietary fat loss. The Investigator will conduct the study and analyze the samples at Mayo Clinic in Rochester, Minnesota.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Alpha-cyclodextrin
- RADIATION Triolein radiolabeled with 100 microcuries of 3^Hydrogen
- RADIATION Tripalmitin radiolabeled with 20 microcuries of 14^Carbon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-01-20 |
| Est. Completion | 2017-06-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002168
The ClinicalTrials.gov registry entry for NCT03002168 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03002168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002168 about?
NCT03002168 is a clinical study titled "Determining Lipid Content in Stool After Alpha-cyclodextrin". The Investigator hypothesizes that the currently used dose of dietary ingredient alpha-cyclodextrin (α-CD) will result in greater loss of dietary fat in the stool compared with placebo. The proposed studies will address the degree to which α-CD increases dietary fat loss. The Investigator will cond...
What is the current status of trial NCT03002168?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2017-01-20. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT03002168?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Alpha-cyclodextrin (DIETARY_SUPPLEMENT), Triolein radiolabeled with 100 microcuries of 3^Hydrogen (RADIATION), Tripalmitin radiolabeled with 20 microcuries of 14^Carbon (RADIATION).
Who is sponsoring clinical trial NCT03002168?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.